Serge Muyldermans PhD

Serge Muyldermans obtained a PhD at the ‘Vrije Universiteit Brussel’, Brussels, Belgium in 1982. He was a postdoc at this university at the time the functional Heavy-chain only antibodies were discovered in camelids. He developed a streamlined method to identify rapidly the antigen-specific, single-domain antibody fragments derived from the unique Heavy chain antibodies of cameldids, This technology was used to found Ablynx NV in December 2001, a Belgian private biotech company actively developing protein therapeutics based on single variable domains or NanobodiesTM and currently employing 300 people.